**Dupixent – Prix Galien 2021**

**SECTION 6: PUBMED**

*References*

1. Dupixent Prescribing Information. June 2020.

2. Gandhi NA, BL Bennett, NM Graham, et al. Targeting key proximal drivers of type 2 inflammation in disease. *Nat Rev Drug Discov.* 2016;15(1):35-50.

3. Data on file.

4. Dupixent (dupilumab). U.S. Prescribing Information. 2020.

5. “DUPIXENT® (DUPILUMAB) EOSINOPHILIC ESOPHAGITIS TRIAL MEETS BOTH CO-PRIMARY ENDPOINTS.” 22 May 2020. Press Release. Accessed at: <https://newsroom.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-eosinophilic-esophagitis-trial-meets-both-co>

6. Snapper CM, Finkelman FD, Paul WE. Regulation of IgG1 and IgE production by interleukin 4. Immunological reviews. 1988 Apr 1;102(1):51-75.

7. Aversa G, Punnonen J, Cocks BG, de Waal Malefyt R, Vega F, Zurawski SM, Zurawski G, De Vries JE. An interleukin 4 (IL-4) mutant protein inhibits both IL-4 or IL-13-induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: support for a common component shared by IL-4 and IL-13 receptors. Journal of Experimental Medicine. 1993 Dec 1;178(6):2213-8.

8. Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. *Proc Natl Acad Sci USA.* 2014;111(14):5147-52.

**Pub Med List**

Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. *N Engl J Med.*2013;368(26):2455-2466.

Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. *Proc Natl Acad Sci USA.* 2014;111(14):5147-52.

Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. *Proc Natl Acad Sci USA.* 2014;111(14):5153-8.

Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. *N Engl J Med.*2014;371(2):130-139.

Thaçi, D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. *Lancet.*2016;387(10013):40-52.

Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis a randomized clinical trial. *JAMA.* 2016;315(5):469-479.

Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta-agonist: a pivotal dose-ranging study. *Lancet*. 2016;388(10039):31-44.

Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. *N Engl J Med*. 2016;375(24):2335-2348.

Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled phase 3 trial. *Lancet*. 2017;389(10086):2287-2303.

Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. *N Engl J Med.* 2018;378:2486-2496.

Rabe KF, Nair P, Brusselle G, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. *N Engl J Med.* 2018;378:2475-2485.

# Bachert C, Han J, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. *Lancet*. 2019;10209:1638-1650.

# Simpson E, Paller A, Siegfried E, et al. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis. *JAMA*. 2019;156(1):44-56.

# Cork M, Thaci D, Eichenfield L, et al. A study of dupilumab in the treatment of adolescents with eczema. *BJD*. 2020;182:85-96.

# Beck L, Thaci D, Deleuran M, et al. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. *Am J Clin Dermatol*. 2020.

# Paller A, Siegfried E, Thaci D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. *JAAD*. 2020.